Molecular dynamics simulations and MM/GBSA methods to investigate binding mechanisms of aminomethylpyrimidine inhibitors with DPP-IV.

The aminomethylpyrimidines were investigated as a novel class of DPP-IV inhibitors. In this Letter, the binding mechanisms of how slight change of substitution or position influences the binding affinity of five representative analogs was investigated by molecular dynamics simulation, free energy calculations and energy decomposition analysis. The conserved hydrogen bonds with Glu205 and Glu206 slightly favor the inhibitor binding; the van der Waals interactions, especially the two key contacts with Tyr547 and Tyr666, dominate in the binding free energy and play a crucial role on distinguishing the high active inhibitors from the low ones.

[1]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[2]  Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. , 2004, Journal of medicinal chemistry.

[3]  Koen Augustyns,et al.  Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes , 2005 .

[4]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[5]  M. Pal,et al.  Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. , 2009, Bioorganic & medicinal chemistry.

[6]  W. C. Still,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999 .

[7]  J. Trevillyan,et al.  “The next big thing” in diabetes: clinical progress on DPP‐IV inhibitors , 2006 .

[8]  Xiaojie Xu,et al.  Recent Advances in Free Energy Calculations with a Combination of Molecular Mechanics and Continuum Models , 2006 .

[9]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[10]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[11]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[12]  C. Deacon.  Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes , 2007, Expert opinion on investigational drugs.

[13]  Kenneth D. Jordan,et al.  Comparison of Density Functional and MP2 Calculations on the Water Monomer and Dimer , 1994 .

[14]  D. Kassel,et al.  Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. , 2007, Journal of medicinal chemistry.

[15]  P. Van der Veken,et al.  Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes , 2003 .

[16]  Walter Huber,et al.  Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. , 2003, Structure.

[17]  D. Kassel,et al.  Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[18]  Silja Weber,et al.  Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. , 2004, Bioorganic & medicinal chemistry letters.

[19]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[20]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[21]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[22]  T. Hughes,et al.  1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. , 2003, Journal of medicinal chemistry.

[23]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[24]  K. Longenecker,et al.  Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2006, Journal of medicinal chemistry.

[25]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[26]  B. Ahrén.  DPP-4 inhibitors. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[27]  Holger Gohlke,et al.  Converging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf , 2004, J. Comput. Chem..

[28]  B. Ahrén.  Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties , 2006, Expert opinion on investigational drugs.

[29]  Biching Sang,et al.  Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation , 2004, Protein science : a publication of the Protein Society.

[30]  C. Deacon.  Therapeutic strategies based on glucagon-like peptide 1. , 2004, Diabetes.

[31]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[32]  Ken Chen,et al.  Prediction of binding affinities between the human amphiphysin-1 SH3 domain and its peptide ligands using homology modeling, molecular dynamics and molecular field analysis. , 2005, Journal of proteome research.

[33]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.